Charlotte titlestad

We enrolled participants of either sex aged years with inadequately controlled moderate-to-severe asthma for 12 months or more, requiring treatment with inhaled corticosteroids at a stable dose. We randomly assigned participants to receive tralokinumab mg or placebo by an interactive web-based system or voice response system. Participants and study personnel were masked to treatment allocation.

Both tralokinumab and placebo were administered subcutaneously every 2 weeks. The primary outcome measure was change from baseline to week 12 in bronchial biopsy eosinophil count. Secondary outcome measures included change in blood and sputum eosinophil counts. Safety analyses were carried out in all participants who received study drug. This trial is registered with ClinicalTrials.

Findings: Between Sept 25, , and June 21, , participants were enrolled and screened. With my vast product and destination knowledge, senior experience and personal service, I believe I can provide you a memorable trip that best suits you. I look forward to assisting you with your future travels, and exceeding your expectations. COM Consultation by appointment. PHONE Please wait 15 minutes and try again or reset your password. Languages English. Contact Dianne Contact. Forgot Your Password?

Enter the email address you used to create your account. Password Forgot your password? You have 1 more login attempt before your account will be temporarily locked. Reset Password Now. Instructions to reset your password have been sent to the email address you provided.